A stylized, golden-colored graphic of a human figure in a dynamic, slightly bent posture, positioned behind the title text. The figure is composed of thick lines and circular joints.

**Skin Perfusion  
Behaviour  
in the posterior  
stump skin of a  
trans tibial amputee**

**Shaun Fealey**

**Supervisor  
Dr Andrew Nunn**

**REHAB Tech-** Monash Rehabilitation Technology Research Unit assume no liability for any claim of adverse effects resulting from misapplication of the information presented here in. While every effort is made to ensure the accuracy of the guide no responsibility or liability will be taken for any inaccuracies.

**REHABTech is finance and supported by**



**In collaboration with**



© Copyright 1998

All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording or any information storage and retrieval system, without permission in writing from the publisher.

Requests for permission to make copies of any part of the work should be addressed to:

**REHAB Tech-** Monash Rehabilitation Technology Research Unit

C/- C.G.M.C.

260 - 294 Kooyong Road

**CAULFIELD VIC 3162**

**AUSTRALIA**

**Email** [rehab.tech@eng.monash.edu.au](mailto:rehab.tech@eng.monash.edu.au)

The Skin Response study aimed to better understand changes in the re-perfusion behaviour of the small blood vessels in the posterior stump skin of a trans tibial amputee in weeks post operation. Using the Skin Pressure Monitor developed by previous Maskiell Research fellow, Tom Churchwood. Subjects were tested weekly over a 5 - 6 week period.

#### Hypothesis

- ◇ Baseline blood flow would be greater in stump than normal side in the initial phase of amputation.
- ◇ Hyperaemia would be greater in stump than normal side at least initially after amputation.
- ◇ This difference between the stump and the normal sides would reduce over time.

#### Results showed

- ◇ .Tendency for Hyperaemia to increase to a maximum with respect to baseline flow, between weeks 2 - 4 post operation, then a periodic decrease over following weeks to correlate with normal side.
- ◇ Blood flow and hyperaemia were variable week to week
- ◇ Caffeine and Nicotine vary both the Hyperaemic Response and Baseline blood flow.
- ◇ Pseudo ephedrine effects both the Hyperaemic Response and baseline blood flow.

## INTRODUCTION

### *Skin Physiology*

Blood flow to the skin has two functions




fig 1 *The Skin Circulation*


### **Regulation of blood flow**

Blood flow can vary from as little as 50ml per minute in severe cold to 2 - 3 litres per minute in extreme heat, through regulation of vascular structures in subcutaneous tissue

### **Supplying Nutrition**

Normal blood flow greatly exceeds the required amount to supply nutrition. This function does not alter blood flow.

### *Concept of Reactive Hyperaemia*



**Fig 2** *Typical Reactive*

### *Hyperaemic Response Observed*

When an area of tissue is compressed so hard that blood is forced out of small vessels supplying the skin. The lack of blood rejuvenation creates a build up of CO<sub>2</sub> and Lactic Acid. This in addition to neural effects brought on by the compression, creates an exaggerated influx of blood when pressure is released, caused directly by the dilation of smaller vessels and the constriction of larger vessels. This provides skin with the blood supply required to regain homeostasis.

### *Relevance to Prosthetic Industry*

The re-perfusion of skin is of particular importance in the Prosthetic Industry as amputees commonly suffer from pressure related complications. A better understanding of how re-perfusion is affected by the amputation, and the period needed for recovery, and vulnerability of a particular individuals skin to load would assist in the amputee management, and provide a potential stress test for skin.

### *DRT4 and Instrumentation*

#### *Laser Doppler Perfusion and Temperature Monitor*

The DRT4 is a dual channel Laser Doppler Perfusion and Temperature Monitor. It incorporates Laser Flowmetry to measure local blood flow, speed or concentration at two separate sites simultaneously. Skin temperature can also be measured simultaneously at the same site.

#### *Laser Doppler Flowmetry*

Laser Flowmetry is a noninvasive method of blood flow measurement. A low powered laser is emitted to the skin at a set frequency through an optic fibre, where the frequency is altered by the concentration and speed of the blood cells it contacts. A beam is returned to the monitor via another optic fibre and the change in frequency used to calculate blood flow.

## *Skin Pressure Monitor*

*[Original Set up see Appendix 2.]*

### *Modifications of Original set up*

Stand was discarded, and arm rest was clamped to an adjustable table.

### **Criteria for change**

- *Measurement of specific site*
- *Reduction of movement of area tested and fibre optic probe movement artifact.*

### **Measurement of specific site.**

All subjects were of different size with different length stumps. Initial stand had been designed for use on a wide range of sites. With a specific site to test protocol was able to be improved.

Adjustable table enabled all subjects to remain in their wheelchairs while being tested.

#### *Test Protocol*

- *Wheelchair position in front of table*
- *Subject stump placed on rest plate and positioned directly over probe.*
- *Table height adjusted so probe and stump were at 90°.*

### **Reduction of Movement**

Laser Doppler Flowmetry is extremely sensitive to movement. To obtain accurate results both probe and subject had to be as stationary as possible.

*Movement was reduced in 2 ways.*

- *Enabling patient to stay in wheelchair meant they stayed comfortable and could remain still longer.*
- *Probe and rest plate clamped to a solid base meant probe remained still.*

## METHODS

### ◇ Selection

Subjects were chosen from the CGMC Rehabilitation ward. All were trans tibial amputees in the first weeks post amputation. Subjects were chosen irrespective to age and sex, with medical conditions such as diabetes and pulmonary vascular disease noted.

### ◇ Protocol

As a participant, subjects were tested at the same site at the same time weekly for a period of 4 - 6 weeks. An infrared tympanic thermometer was used to measure skin and room temperature before each test.

## A. Pressure Response

### ◇ Test Protocol

1. Stump placed on probe
2. Baseline monitored for 100 seconds
3. 240 mm Hg pressure applied for 60 seconds
4. Pressure released
5. Hyperaemic response recorded for 30 seconds
6. 3 - 5 repeated three times
7. 1 - 6 repeated on normal leg

### ◇ Analysis




Fig 4 Analysis of Hyperaemic Response Curve

Using DRTSOFT the following were calculated from respective 30 second time slices

- Mean Baseline Blood Flow
- Baseline Area
- Response Curve Area

To find the most useful representation of the hyperaemic response recorded two calculations were recorded

- Response curve area  
[Average of the three 30 second response curves recorded]
- Response Curve Area - Baseline Area  
[Above value minus Baseline Blood Flow Area]  
[See Fig 4]

For direct comparison between sides a ratio of stump side with respect to normal side was produced. This made observation of changes simpler

- Ratio less than one  
⇒ *Normal side greater than Stump side*
- Ratio equal to one  
⇒ *Normal side equal to Stump side*
- Ratio greater than one  
⇒ *Normal side less than Stump side*

Two final ratios were calculated

- Response Curve Area / Baseline Area  
⇒  $[ R / B ]$
- (Response Curve Area - Baseline Area) / Baseline Area  
⇒  $[ ( R - B ) / B ]$

These gave a better idea of the relationship of baseline to response irrespective of the values which tended to vary week to week.

**Table 1** Example of Analysis Spreadsheet

|           | Baseline | Baseline Area | Area Curve 1 | Area Curve 2 | Mean Area | Diff B/w areas | (Cu-Ba)/Ba | Curve/Base |
|-----------|----------|---------------|--------------|--------------|-----------|----------------|------------|------------|
| Sub1AmpR  | 14.90    | 448.00        | 766.70       | 697.50       | 732.10    | 284.10         | 0.63       | 1.63       |
| Sub1NormL | 8.90     | 267.60        | 387.10       | 333.80       | 360.45    | 92.85          | 0.35       | 1.35       |
| Amp/Norm  | 1.67     | 1.67          | 1.98         | 2.09         | 2.03      | 3.06           | 1.83       | 1.21       |
| Sub2AmpR  | 5.10     | 151.80        | 379.80       | 310.40       | 345.10    | 193.30         | 1.27       | 2.27       |
| Sub2NormL | 5.80     | 174.50        | 228.20       | 221.40       | 224.80    | 50.30          | 0.29       | 1.29       |
| Amp/Norm  | 0.88     | 0.87          | 1.66         | 1.40         | 1.54      | 3.84           | 4.42       | 1.76       |

Selected results were then plotted for each subject against weeks post amputation, and comparisons made.

## *Problems*

The position of the subject and the probe stand during testing proved to be of great importance.

Two factors


### *1. Angle of Probe*

For accurate results it was found extremely important that the site being tested was at right angles with the probe. If this was not the case the site at which pressure was applied and that of the measurement were separate. If this was the case an increase in flow was witnessed when pressure was applied, and response curve was not witnessed at all

### *2. Movement of Patient and Probe*

Previously mentioned.

## *Repeatability of Test Protocol.*



**Fig 5** *Overlay of 3 consecutive Pressure Tests trials*

As demonstrated in fig for all 6 subjects in this study (+ 9 subjects in a prior study) were consistent on 3 consecutive trials on the same day. Variations day to day will be discussed.

## **Other Tests Performed**

### ***B. Caffeine Tests***

Following earlier work showing fluctuation in other amputee subjects tested after tea, coffee, and cigarettes, a study was performed on three subjects (21,22,24 yrs, 2 male 1 female) to study the effect.

#### *Caffeine Test Protocol*

1. Baseline Blood Flow 30 seconds each leg  
*[same test site as pressure test.]*
2. 100mg pure caffeine tablet ingested
3. Step 3 - 5 of *test A* protocol on each leg at 5 minute intervals

Pulse rate was taken at each 5 minutes interval to determine whether increase cardiac output was the contributing factor.


### ***C. Nicotine Tests***

#### *Nicotine Test Protocol*


1. Baseline Blood Flow 30 seconds each leg  
*[same test site as test A.]*
2. 10 mg cigarette ingested.
3. Step 3 - 5 of *test A* protocol on each leg at 5 minute intervals.

# RESULTS


## A. PRESSURE TEST ON AMPUTEES




**Fig 6** Baseline Blood Flow Vs Post Weeks Amputation



**Fig 7** Response Curve Area Vs Post Weeks Amputation



**Fig 8** Curve Area / Baseline Area Vs Weeks Post Amputation



**Fig 9** Response Curve / Baseline Vs Weeks Post Amputation

As discussed variation occurred day - day, not unexpectedly given the multiple local and particularly environmental variables. As such variation in baseline needed to be accounted for, the comparison was drawn between the amputated and intact side for a given individual.


There was a overall trend in figs 6 - 9 plotting results against weeks post amputation. All involved peaking of the response between weeks 2 - 4.

The baseline blood flow over time fig 6 showed a similar trend. The area response curve fig 7 was similarly increased.


Only one subject (3) was tested in the first week post amputation with elevated responses immediately post operatively. figs 6 - 9

The response in subject 1 at weeks 8 - 9 did not follow the pattern, but coincided with stump inflammation due to infection and wound breakdown.


**B. EFFECTS OF CAFFEINE ON NORMAL SUBJECTS**



**Fig 10** 100 mg Caffeine Affect On Response Curve Area



**Fig 11** 100 mg Caffeine Affect On Response Curve Area




**Fig 12** 100 mg Caffeine Affect On Response Curve Area

An increase in blood flux observed in all subjects lasted approximately 30 minutes peaking at 15 minutes. fig 10 - 12

Radial pulse rate did not increase significantly.

### ***C. EFFECTS OF NICOTINE***



**Fig** *Effect Of Nicotine on Response Curve Area Over Time*

Similarly nicotine effect has been shown in prior studies and has confounded at prior studies. The study of 3 subjects showed the most marked increase in subject 1 a smoker.

### ***D. Effect of PseudoEphedrine***

2 subjects in a prior study did not follow the trend were on PE 60 mgms TDS for phantom pain. The effect on this alpha agonist was variable but significantly altered responses.

## **DISCUSSION**

### ***A. Pressure Test On Amputees***

The increase and peaking blood flow in the 2 - 4 week period may reflect changes in the balance between sympathetic and parasympathetic influences on vasomotor tone and needs further work.

### ***B. Caffeine Effect***

Results indicated an increase in blood flux in two normal subjects consistent with prior results which appeared to be independent of heart rate and possibly a peripheral action of caffeine on acetyl choline receptors. This may have implications for not only confounding study results, but also may be helpful in increasing peripheral blood flow where appropriate.

### ***C. Effects Of Nicotine***

Again Nicotine increased the peripheral blood flux with the smoker possibly having sensitised nicotinic receptors and greater response.

The time course was a peak response at 5 minutes with return to baseline in approximately 10 minutes.

### ***D. Effect of Pseudoephedrine.***

Both subjects were on PE for phantom pain and significant hyperalgesia with some effect and further raises the possibility of its action on sympathetically mediated responses in this case in the posterior flap of tran tibial amputees with the stump more affected than the normal leg.

## **CONCLUSION**

The development of the PPR Monitor and the results in this pilot project suggest that reactive hyperaemia occurs and then reduces post amputation

Appendix 1

**SUBJECT 1**

|         | Baseline | Baseline Area | Mean Area | Diff B/w areas | (Cu-Ba)/Ba | Curve/Base |
|---------|----------|---------------|-----------|----------------|------------|------------|
| Sub1AR1 | 5.10     | 151.80        | 345.10    | 193.30         | 1.27       | 2.27       |
| Sub1NL1 | 5.80     | 174.50        | 224.80    | 50.30          | 0.29       | 1.29       |
| A/N     | 0.88     | 0.87          | 1.54      | 3.84           | 4.42       | 1.76       |
| Sub1AR2 | 7.2      | 162.9         | 431.10    | 268.2          | 1.65       | 2.65       |
| Sub1NL2 | 5        | 148.7         | 234.75    | 86.05          | 0.58       | 1.58       |
| A/N     | 1.44     | 1.10          | 1.84      | 3.12           | 2.85       | 1.68       |
| Sub1AR3 | 7.80     | 233.20        | 459.80    | 226.60         | 0.97       | 1.97       |
| Sub1NL3 | 5.40     | 162.00        | 304.85    | 142.85         | 0.88       | 1.88       |
| A/N     | 1.44     | 1.44          | 1.51      | 1.59           | 1.10       | 1.05       |
| Sub1AR4 | 6.70     | 202.50        | 314.50    | 112.00         | 0.55       | 1.55       |
| Sub1NL4 | 5.10     | 149.00        | 223.20    | 74.20          | 0.50       | 1.50       |
| A/N     | 1.31     | 1.36          | 1.41      | 1.51           | 1.11       | 1.04       |
| Sub1AR5 | 10.70    | 320.00        | 367.70    | 47.70          | 0.15       | 1.15       |
| Sub1NL5 | 4.60     | 138.20        | 320.05    | 181.85         | 1.32       | 2.32       |
| A/N     | 2.33     | 2.32          | 1.15      | 0.26           | 0.11       | 0.50       |
| Sub1AR6 | 7.1      | 212.2         | 469.9     | 257.70         | 1.21       | 2.21       |
| Sub1NL6 | 6.1      | 182.7         | 245.3     | 62.60          | 0.34       | 1.34       |
| A/N     | 1.16     | 1.16          | 1.92      | 4.12           | 3.54       | 1.65       |
| Sub1AR7 | 10.40    | 312.40        | 493.12    | 180.72         | 0.58       | 1.58       |
| Sub1NL7 | 5.90     | 175.80        | 263.15    | 87.35          | 0.50       | 1.50       |
| A/N     | 1.76     | 1.78          | 1.87      | 2.07           | 1.16       | 1.05       |

**SUBJECT 2**

|         | Baseline | Baseline Area | Mean Area | Resp area | (Cu-Ba)/Ba | Curve/Base |
|---------|----------|---------------|-----------|-----------|------------|------------|
| Sub2AR1 | 14.90    | 448.00        | 732.10    | 284.10    | 0.63       |            |
| Sub2NL1 | 8.90     | 267.60        | 360.45    | 92.85     | 0.35       | 1.35       |
| A/N     | 1.67     | 1.67          | 2.03      | 3.06      | 1.83       | 1.21       |
| Sub2AR1 | 22.50    | 530.20        | 1404.90   | 874.70    | 1.65       | 2.65       |
| Sub2NL1 | 8.70     | 260.30        | 375.30    | 115.00    | 0.44       | 1.44       |
| A/N     | 2.59     | 2.04          | 3.74      | 7.61      | 3.73       | 1.84       |

**SUBJECT 3**

|         | Baseline | Baseline Area | Mean Area | Resp Curve | (Cu-Ba)/Ba | Curve/Base |
|---------|----------|---------------|-----------|------------|------------|------------|
| Sub3AR1 | 7        | 211.1         | 333.75    | 122.65     | 0.58       | 1.58       |
| Sub3NL1 | 3.4      | 102.5         | 125.7     | 23.20      | 0.23       | 1.23       |
| A/N     | 2.06     | 2.06          | 2.66      | 5.29       | 2.57       | 1.29       |
| Sub3AR2 | 6.1      | 183.7         | 268.1     | 84.4       | 0.46       | 1.46       |
| Sub3NL2 | 8.8      | 264.2         | 325.1     | 60.9       | 0.23       | 1.23       |
| A/N     | 0.69     | 0.70          | 0.82      | 1.39       | 1.99       | 1.19       |
| Sub3AR3 | 11.8     | 352.5         | 628.55    | 276.05     | 0.78       | 1.78       |
| Sub3NL3 | 11.7     | 351.2         | 434.1     | 82.90      | 0.24       | 1.24       |
| A/N     | 1.01     | 1.00          | 1.45      | 3.33       | 3.32       | 1.44       |
| Sub3AR4 | 9.30     | 280.00        | 363.75    | 83.75      | 0.30       | 1.30       |
| Sub3NL4 | 6.70     | 201.40        | 228.90    | 27.50      | 0.14       | 1.14       |
| A/N     | 1.39     | 1.39          | 1.59      | 3.05       | 2.19       | 1.14       |

**SUBJECT 4**

|         | Baseline | Baseline Area | Mean Area | Resp Curve | (Cu-Ba)/Ba | Curve/Base |
|---------|----------|---------------|-----------|------------|------------|------------|
| Sub4AL1 | 6.00     | 178.70        | 314.60    | 135.90     | 0.76       | 1.76       |
| Sub4NR1 | 6.00     | 178.90        | 254.00    | 75.10      | 0.42       | 1.42       |
| A/N     | 1.00     | 1.00          | 1.24      | 1.81       | 1.81       | 1.24       |
| Sub4AL2 | 16       | 478.6         | 584.9     | 106.3      | 0.22       | 1.22       |
| Sub4NR2 | 11       | 330.3         | 479.55    | 149.25     | 0.45       | 1.45       |
| A/N     | 1.45     | 1.45          | 1.22      | 0.71       | 0.49       | 0.84       |
| Sub4AL3 | 11.40    | 341.00        | 486.05    | 145.05     | 0.43       | 1.43       |
| Sub4NR3 | 13.50    | 405.40        | 669.50    | 264.10     | 0.65       | 1.65       |
| A/N     | 0.84     | 0.84          | 0.73      | 0.55       | 0.65       | 0.86       |

**SUBJECT 5**

|         | Baseline | Baseline Area | Mean Area | Resp Curve | (Cu-Ba)/Ba | Curve/Base |
|---------|----------|---------------|-----------|------------|------------|------------|
| Sub5AR1 | 15.6     | 467.5         | 1081.3    | 613.8      | 1.31       | 2.31       |
| Sub5NL1 | 12.7     | 379.9         | 570       | 190.1      | 0.50       | 1.50       |
| A/N     | 1.23     | 1.23          | 1.90      | 3.23       | 2.62       | 1.54       |
| Sub5AR2 | 7.4      | 222.2         | 412.35    | 190.15     | 0.86       | 1.86       |
| Sub5NL2 | 12.5     | 376.4         | 703.85    | 327.45     | 0.87       | 1.87       |
| A/N     | 0.59     | 0.59          | 0.59      | 0.58       | 0.98       | 0.99       |

**SUBJECT 6**

|         | Baseline | Baseline Area | Mean Area | Resp Area | (Cu-Ba)/Ba | Curve/Base |
|---------|----------|---------------|-----------|-----------|------------|------------|
| Sub6AL1 | 5.60     | 168.50        | 181.95    | 13.45     | 0.08       | 1.08       |
| Sub6NR1 | 3.90     | 115.70        | 149.75    | 34.05     | 0.29       | 1.29       |
| A/N     | 1.44     | 1.46          | 1.22      | 0.40      | 0.27       | 0.83       |
| Sub6AL2 | 7.30     | 218.80        | 409.50    | 190.70    | 0.87       | 1.87       |
| Sub6NR2 | 3.90     | 116.50        | 126.70    | 10.20     | 0.09       | 1.09       |
| A/N     | 1.87     | 1.88          | 3.23      | 1.87      | 9.95       | 1.72       |
| Sub6AL3 | 11.20    | 335.80        | 365.20    | 29.40     | 0.09       | 1.09       |
| Sub6NR3 | 4.90     | 148.00        | 141.50    | -6.50     | -0.04      | 0.96       |
| A/N     | 2.29     | 2.27          | 2.58      | 4.52      | 1.99       | 1.14       |
| Sub6AL4 | 13.7     | 409.9         | 664.45    | 254.55    | 0.62       | 1.62       |
| Sub6NR4 | 8.7      | 260.9         | 314.60    | 53.70     | 0.21       | 1.21       |
| A/N     | 1.57     | 1.57          | 2.11      | 4.74      | 3.02       | 1.34       |
| Sub6AL5 | 9.30     | 277.90        | 623.80    | 345.90    | 1.24       | 2.24       |
| Sub6NR5 | 11.70    | 351.50        | 515.30    | 163.80    | 0.47       | 1.47       |
| A/N     | 0.79     | 0.79          | 1.21      | 2.11      | 2.67       | 1.53       |

**SUBJECT 7**

|         | Baseline | Baseline Area | Mean Area | Resp Curve | (Cu-Ba)/Ba | Curve/Base |
|---------|----------|---------------|-----------|------------|------------|------------|
| Sub7AR1 | 5.7      | 169.5         | 306.9     | 137.40     | 0.81       | 1.81       |
| Sub7NL1 | 6.2      | 185.3         | 229.65    | 44.35      | 0.24       | 1.24       |
| A/N     | 0.92     | 0.91          | 1.34      | 3.10       | 3.39       | 1.46       |
| Sub7AR2 | 4.4      | 133.1         | 348.2     | 215.1      | 1.62       | 2.62       |
| Sub7NL2 | 5.2      | 155.1         | 274.3     | 119.2      | 0.77       | 1.77       |
| A/N     | 0.85     | 0.86          | 1.27      | 1.80       | 2.10       | 1.48       |
| Sub7AR3 | 7.20     | 215.00        | 489.30    | 274.30     | 1.28       | 2.28       |
| Sub7NL3 | 4.20     | 125.40        | 238.40    | 113.00     | 0.90       | 1.90       |
| A/N     | 1.71     | 1.71          | 2.05      | 2.43       | 1.42       | 1.20       |

*Appendix 2*  
*Skin Pressure Monitor*